文献速递淋巴瘤血栓与止血

特发性多中心Castleman病TAFRO亚型的国际验证定义

Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease.
PubMed 文献 · Am J Hematol · 2021-07-28

该研究通过系统综述和队列分析,检索PubMed和日本医学摘要学会数据库,提取54例TAFRO病例,将病例分为iMCD-TAFRO、可能iMCD-TAFRO及无iMCD的TAFRO三类,并提出国际定义:需满足四项临床标准(血小板减少、全身水肿、发热/高炎症状态、器官肿大)、肾功能不全或特征性骨髓表现、以及淋巴结特征符合iMCD。该定义在ACCELERATE自然史注册中心外部队列中得到验证。

要点

  • iMCD-TAFRO国际定义要求四项临床标准、肾功能不全或特征性骨髓表现、淋巴结特征符合iMCD。
  • 定义基于54例文献病例的系统综述,并在ACCELERATE外部队列中验证。
  • 该定义有助于更精确、全面地诊断iMCD-TAFRO。

核心结论

  • 建立了iMCD-TAFRO的国际定义,并在外部队列中验证,可促进更精确和全面的诊断。

研究设计与样本

  • 系统综述和队列分析,检索PubMed和日本医学摘要学会数据库,关键词为「TAFRO」,排除可能系统性自身免疫病和血液系统恶性肿瘤,共纳入50篇文章的54例病例。

主要发现

  • 将病例分为三类:iMCD-TAFRO(TAFRO综合征且淋巴结病理符合iMCD)、可能iMCD-TAFRO(未行淋巴结活检且无其他合并症)、无iMCD或其他合并症的TAFRO(淋巴结病理不符合iMCD或有其他合并症)。

关键数值与推荐

  • 国际定义要求四项临床标准(血小板减少、全身水肿、发热/高炎症状态、器官肿大),以及肾功能不全或特征性骨髓表现,以及淋巴结特征符合iMCD。

临床怎么用

  • 该定义可用于临床诊断iMCD-TAFRO,辅助识别符合iMCD的TAFRO综合征患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly (TAFRO) syndrome is a heterogeneous entity manifesting with a constellation of symptoms described above that can occur in the context of idiopathic multicentric Castleman disease (iMCD) as well as infectious diseases, malignancies, and rheumatologic disorders. So, iMCD-TAFRO is an aggressive subtype of iMCD with TAFRO syndrome and often hyper-vascularized lymph nodes. Since we proposed diagnostic criteria of iMCD-TAFRO in 2016, we have accumulated new insights on the disorder and additional cases have been reported worldwide. In this systematic review and cohort analysis, we established and validated a definition for iMCD-TAFRO. First, we searched PubMed and Japan Medical Abstracts Society databases using the keyword "TAFRO" to extract cases. Patients with possible systemic autoimmune diseases and hematologic malignancies were excluded. Our search identified 54 cases from 50 articles. We classified cases into three categories: (1) iMCD-TAFRO (TAFRO syndrome with lymph node histopathology consistent with iMCD), (2) possible iMCD-TAFRO (TAFRO syndrome with no lymph node biopsy performed and no other co-morbidities), and (3) TAFRO without iMCD or other co-morbidities (TAFRO syndrome with lymph node histopathology not consistent with iMCD or other comorbidities). Based on the findings, we propose an international definition requiring four clinical criteria (thrombocytopenia, anasarca, fever/hyperinflammatory status, organomegaly), renal dysfunction or characteristic bone marrow findings, and lymph node features consistent with iMCD. The definition was validated with an external cohort (the ACCELERATE Natural History Registry). The present international definition will facilitate a more precise and comprehensive approach to the diagnosis of iMCD-TAFRO.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Nishimura Y, Fajgenbaum DC, Pierson SK, et al. Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease. Am J Hematol. 2021. PMID: 34265103. doi:10.1002/ajh.26292

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。